| Working Paper |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| A Breath of Fresh Air? Firm Type, Scale, Scope and Selection Effects in Drug Development |
0 |
0 |
0 |
0 |
0 |
1 |
16 |
238 |
| A Breath of Fresh Air? Firm types, scale, scope and selection effects in drug development |
0 |
0 |
0 |
52 |
1 |
1 |
7 |
237 |
| A Comparison of U.S. And European University-Industry Relations in the Life Sciences |
0 |
0 |
0 |
0 |
0 |
1 |
19 |
414 |
| A Comparison of U.S. and European University-Industry Relations in the Life Sciences |
0 |
0 |
0 |
65 |
1 |
2 |
15 |
360 |
| A Generalized Preferential Attachment Model for Business Firms Growth Rates: I. Empirical Evidence |
0 |
0 |
0 |
4 |
1 |
2 |
8 |
49 |
| A Generalized Preferential Attachment Model for Business Firms Growth Rates: I. Empirical Evidence |
0 |
0 |
0 |
10 |
0 |
0 |
11 |
92 |
| A Generalized Preferential Attachment Model for Business Firms Growth Rates: II. Mathematical Treatment |
0 |
0 |
0 |
5 |
1 |
1 |
14 |
99 |
| A Generalized Preferential Attachment Model for Business Firms Growth Rates: II. Mathematical Treatment |
0 |
0 |
0 |
3 |
1 |
2 |
9 |
75 |
| A Public-Private Insurance Model for Natural Risk Management: an Application to Seismic and Flood Risks on Residential Buildings in Italy |
0 |
0 |
0 |
12 |
1 |
1 |
5 |
32 |
| Access to Medicines and European Market Integration |
0 |
0 |
0 |
31 |
0 |
1 |
13 |
97 |
| Alcuni vantaggi "minori" del contributivo: Ricongiunzione e Totalizzazione |
0 |
0 |
0 |
9 |
0 |
0 |
9 |
85 |
| Assessing financial distress dependencies in OTC markets: a new approach by Trade Repositories data |
0 |
0 |
0 |
26 |
1 |
1 |
7 |
63 |
| Auctions vs. Bargaining: An Empirical Analysis of Medical Device Procurement |
0 |
0 |
0 |
149 |
1 |
2 |
12 |
512 |
| Better to stay apart: asset commonality, bipartite network centrality, and investment strategies |
0 |
0 |
0 |
5 |
1 |
3 |
16 |
77 |
| Betweenness Centrality of Fractal and Non-Fractal Scale-Free Model Networks and Tests on Real Networks |
0 |
0 |
0 |
24 |
0 |
0 |
7 |
152 |
| Co-evolution of Organizational Forms and Technology |
0 |
0 |
0 |
0 |
0 |
1 |
8 |
257 |
| Competencies, Technological Change and Network Dynamics. The case of the bio-pharmaceutical industry |
0 |
0 |
0 |
234 |
0 |
1 |
7 |
465 |
| Crescita, occupazione e sostenibilità - Il ruolo delle infrastrutture digitali |
0 |
0 |
0 |
14 |
0 |
0 |
5 |
93 |
| Demography, Sustainability, and Growth Notes on the future of the European "Social Market" Economy |
0 |
0 |
0 |
48 |
1 |
9 |
16 |
158 |
| Dinamiche di mercato e intensità della concorrenza di prezzo nel segmento dei farmaci off patent. La posizione dell'Italia nel contesto europeo |
0 |
0 |
0 |
56 |
1 |
1 |
8 |
198 |
| Dynamic Competition in Pharmaceuticals: Patent Expiry, Generic Penetration, and Industry Structure |
0 |
0 |
0 |
150 |
0 |
1 |
23 |
537 |
| Federalismo e riparto del Fsn-2011: Much Ado About Nothing? |
0 |
0 |
0 |
15 |
0 |
4 |
9 |
189 |
| Generici vs. Branded: confronto internazionale su prodotti off-patent rimborsati dal SSN |
0 |
0 |
0 |
16 |
0 |
0 |
7 |
105 |
| Gli andamenti della spesa sanitaria: l'Italia in una sintetica comparazione internazionale |
0 |
0 |
0 |
21 |
0 |
9 |
14 |
92 |
| Global Competitiveness in Pharmaceuticals: A European Perspective |
0 |
0 |
3 |
149 |
0 |
2 |
27 |
482 |
| Global ownership and corporate control networks |
0 |
1 |
2 |
55 |
0 |
2 |
31 |
199 |
| I Farmaci Oncologici in Italia: innovazione e sostenibilità economica |
0 |
0 |
0 |
54 |
0 |
0 |
5 |
242 |
| I farmaci ospedalieri tra Europa, Stato, Regioni e Cittadini |
0 |
0 |
0 |
17 |
0 |
0 |
6 |
110 |
| I numeri del Federalismo in Sanità - Benchmark e Standard per la Sanità Italiana, in attesa della decretazione attuativa della Legge n. 42-2009 |
0 |
0 |
0 |
16 |
0 |
0 |
4 |
101 |
| I numeri del Federalismo in Sanità - Benchmarking e Standard su profili di spesa sanitaria per età |
0 |
0 |
0 |
46 |
0 |
0 |
5 |
143 |
| I numeri del federalismo: una simulazione per la sanità |
0 |
0 |
0 |
10 |
0 |
0 |
11 |
87 |
| I trend della spesa sanitaria e le ragioni del finanziamento multipillar con componente ad accumulazione reale |
0 |
0 |
1 |
13 |
0 |
0 |
12 |
120 |
| Il Decreto DL 15/04/2002, n. 63 sul Contenimento della Spesa Farmaceutica - Impatto sull'Industria e Distorsioni nel Funzionamento del Mercato |
0 |
0 |
0 |
14 |
1 |
1 |
22 |
136 |
| Il disegno delle nuove agevolazioni fiscali alla previdenza complementare - una quantificazione per un lavoratore dipendente neoassunto del settore privato |
0 |
0 |
0 |
9 |
0 |
0 |
9 |
70 |
| Il prezzo di riferimento nel quadro regolatorio del mercato farmaceutico |
0 |
0 |
0 |
23 |
0 |
1 |
8 |
152 |
| In attesa del federalismo compiuto: LEA, spesa sanitaria e risorse finanziarie a livello regionale |
0 |
0 |
0 |
20 |
1 |
1 |
4 |
107 |
| Inflazione, bassa crescita, Euro forte: tra problemi europei ed economia globale |
0 |
0 |
0 |
14 |
0 |
0 |
8 |
102 |
| Innovation and Corporate Dynamics: A Theoretical Framework |
0 |
0 |
0 |
151 |
0 |
0 |
21 |
282 |
| Innovation and Corporate Dynamics: A Theoretical Framework |
0 |
0 |
0 |
67 |
0 |
2 |
16 |
147 |
| Innovation and Corporate Growth in the Evolution of the Drug Industry |
0 |
0 |
1 |
432 |
0 |
1 |
18 |
1,002 |
| Introduzione. Liberalizzazioni e concorrenza in Italia |
0 |
0 |
1 |
27 |
0 |
0 |
11 |
158 |
| L'integrazione pubblico-privato in sanità e assistenza alla persona |
0 |
0 |
0 |
18 |
0 |
0 |
7 |
109 |
| La Riforma del Welfare, il Paygo, i nuovi Ammortizzatori per il Mercato del Lavoro |
0 |
0 |
0 |
12 |
0 |
0 |
10 |
122 |
| La Sostenibilità dei Sistemi Sanitari Regionali |
0 |
0 |
0 |
32 |
0 |
0 |
7 |
141 |
| La Sostenibilità dei Sistemi Sanitari Regionali - SaniMod-Reg 2012-2030 |
0 |
0 |
0 |
31 |
0 |
0 |
5 |
138 |
| La distribuzione al dettaglio dei farmaci - tra regolazione efficiente e mercato |
0 |
0 |
1 |
33 |
1 |
10 |
16 |
299 |
| La nuova fiscalità della previdenza complementare per il lavoratore, l'impresa e l'Erario - Una quantificazione per il lavoratore dipendente neoassunto del settore privato con turnover decennale di datore di lavoro |
0 |
0 |
0 |
16 |
0 |
0 |
6 |
86 |
| La regolamentazione delle farmacie in Italia |
0 |
0 |
0 |
23 |
0 |
0 |
8 |
126 |
| La sanità in Italia - tra federalismo, regolazione dei mercati e sostenibilità delle finanze pubbliche |
0 |
0 |
1 |
28 |
0 |
0 |
7 |
120 |
| La spesa farmaceutica pubblica - Analisi degli ultimi anni e indicazioni per una nuova politica economica |
0 |
0 |
1 |
18 |
0 |
0 |
9 |
83 |
| La spesa farmaceutica territoriale convenzionata: il modello FarmaRegio per l'analisi della variabilità regionale |
1 |
1 |
3 |
19 |
1 |
1 |
11 |
131 |
| La spesa sanitaria delle Regioni in Italia - Saniregio 2015 |
0 |
0 |
0 |
76 |
1 |
1 |
11 |
300 |
| La spesa sanitaria delle Regioni in Italia - Saniregio 3 |
0 |
0 |
1 |
59 |
1 |
1 |
11 |
235 |
| La spesa sanitaria delle Regioni in Italia - Saniregio2017 |
0 |
0 |
2 |
63 |
0 |
2 |
22 |
231 |
| La spesa sanitaria pubblica in Italia: dentro la "scatola nera" delle differenze regionali - Il modello SaniRegio |
0 |
0 |
3 |
149 |
0 |
1 |
12 |
415 |
| Le differenze regionali nella governance della spesa sanitaria - SaniRegio-2011 |
0 |
0 |
0 |
59 |
0 |
0 |
7 |
219 |
| Le differenze regionali nella governance della spesa sanitaria. La sanità alla sfide del federalismo: il modello SaniRegio di CeRM |
0 |
0 |
0 |
17 |
0 |
0 |
11 |
116 |
| Le proiezioni della spesa sanitaria Ssn - SaniMod 2011-2030 |
0 |
0 |
0 |
59 |
1 |
2 |
16 |
238 |
| Le proiezioni di lungo periodo della spesa sociale nell'UE: l'impatto demografico e il possibile impatto della tecnologia sulla spesa sanitaria |
0 |
0 |
0 |
21 |
0 |
10 |
17 |
122 |
| Market Structure and Drug Innovation |
0 |
0 |
0 |
30 |
0 |
2 |
8 |
152 |
| Medical Devices Competitiveness and Impact on Public Health Expenditure |
0 |
0 |
1 |
192 |
1 |
2 |
31 |
819 |
| Medical Devices: Competitiveness and Impact on Public Health Expenditure |
0 |
0 |
0 |
33 |
0 |
1 |
15 |
197 |
| Mezzogiorno d'Italia - Primo Baedeker dello sviluppo territoriale e regionale |
0 |
0 |
0 |
19 |
2 |
2 |
4 |
108 |
| Networks Dynamics in the Pharmaceutical Industry |
0 |
0 |
0 |
1 |
1 |
1 |
5 |
259 |
| Networks of innovators within and across borders. Evidence from patent data |
0 |
0 |
0 |
114 |
2 |
3 |
15 |
263 |
| Nuove politiche per l'innovazione nel settore delle scienze della vita |
0 |
0 |
0 |
7 |
0 |
0 |
9 |
109 |
| Occupazione, produttività e demografia: le sfide per la crescita del Mezzogiorno - Riforme strutturali per dare basi al federalismo |
0 |
0 |
0 |
8 |
1 |
1 |
11 |
85 |
| On Firm Growth in Networks |
0 |
0 |
0 |
20 |
0 |
0 |
5 |
118 |
| On Size and Growth of Business Firms |
0 |
0 |
0 |
35 |
1 |
1 |
8 |
348 |
| Opting-out previdenziale, smobilizzo del TFR e basi strutturali del pilastro privato |
0 |
0 |
0 |
9 |
0 |
0 |
4 |
76 |
| Patent Disclosure and R&D Competition in Pharmaceuticals |
0 |
0 |
0 |
110 |
1 |
3 |
19 |
215 |
| Patent Disclosure and R&D Competition in Pharmaceuticals |
0 |
0 |
0 |
117 |
0 |
1 |
17 |
341 |
| Patent Value and R&D Competition |
0 |
0 |
0 |
2 |
0 |
0 |
6 |
112 |
| Peer-Group Detection of Banks and Resilience to Distress |
0 |
0 |
0 |
14 |
0 |
0 |
14 |
81 |
| Preferential attachment and growth dynamics in complex systems |
0 |
0 |
0 |
19 |
0 |
0 |
10 |
125 |
| Processes of corporate growth in the evolution of an innovation-driven industry. The case of pharmaceuticals |
0 |
0 |
0 |
251 |
0 |
0 |
8 |
533 |
| Quali Regole per la Spesa Farmaceutica? - Criticità, Impatti, Proposte |
0 |
0 |
2 |
13 |
1 |
1 |
13 |
73 |
| R&D, Within and Between Patent Competition in the Pharmaceutical Industry |
0 |
0 |
0 |
174 |
1 |
2 |
12 |
387 |
| Regolazione, innovazione e ciclo di vita dei prodotti - per una riforma del pricing al lancio e della governance della spesa nella farmaceutica pubblica |
0 |
0 |
0 |
16 |
0 |
0 |
14 |
131 |
| Regole pensionistiche e incentivi al prolungamento della vita lavorativa: analisi del caso italiano |
0 |
0 |
0 |
22 |
0 |
1 |
13 |
105 |
| Regole pensionistiche e prolungamento dell'attività: analisi del TIR e effetti del cumulo lavoro-pensione |
0 |
0 |
1 |
13 |
0 |
0 |
24 |
117 |
| Spesa sanitaria, demografia, governance istituzionale - Tra trend storici e proiezioni a lungo termine |
0 |
0 |
0 |
10 |
0 |
0 |
9 |
86 |
| Statistical Properties of Business Firms Structure and Growth |
0 |
0 |
0 |
19 |
3 |
4 |
11 |
101 |
| Structure of Business Firm Networks and Scale-Free Models |
0 |
0 |
0 |
11 |
0 |
0 |
11 |
106 |
| Structure of Business Firm Networks and Scale-Free Models |
0 |
0 |
0 |
53 |
0 |
0 |
9 |
248 |
| Strumenti di regolazione del mercato farmaceutico: un'analisi ragionata |
1 |
1 |
1 |
78 |
2 |
2 |
10 |
236 |
| Systemic importance of financial institutions: from a global to a local perspective? A network theory approach |
0 |
0 |
0 |
93 |
0 |
0 |
9 |
142 |
| Systemic importance of financial institutions: regulations, research, open issues, proposals |
0 |
0 |
0 |
50 |
0 |
0 |
11 |
217 |
| Systemic risk and banking regulation: some facts on the new regulatory framework |
0 |
1 |
1 |
138 |
0 |
1 |
10 |
233 |
| Technological Regimes and the Growth of Networks An Empirical Analysis |
0 |
0 |
0 |
129 |
1 |
1 |
10 |
366 |
| The Accounting Network: how financial institutions react to systemic crisis |
0 |
0 |
0 |
27 |
0 |
2 |
11 |
47 |
| The Growth of Business Firms: Theoretical Framework and Empirical Evidence |
0 |
0 |
0 |
21 |
0 |
1 |
5 |
128 |
| The Growth of Business Firms: Theoretical Framework and Empirical Evidence |
0 |
0 |
0 |
169 |
1 |
1 |
10 |
1,671 |
| The Multipillar System for Health Care Financing: Thirteen Good Reasons for Open Capitalisation Funds, Covering both Pension and Health Care Provisions |
0 |
0 |
0 |
32 |
0 |
0 |
8 |
110 |
| The Nature and the Extent of the Market for Technology in Biopharmaceuticals |
0 |
0 |
0 |
47 |
0 |
0 |
11 |
199 |
| The Size Variance Relationship of Business Firm Growth Rates |
0 |
0 |
0 |
33 |
1 |
1 |
5 |
98 |
| The Size Variance Relationship of Business Firm Growth Rates |
0 |
0 |
0 |
37 |
0 |
1 |
10 |
114 |
| The Size Variance Relationship of Business Firm Growth Rates |
0 |
0 |
0 |
28 |
0 |
1 |
9 |
89 |
| The Sustainability of European Health Care Systems: Beyond Income and Ageing |
0 |
0 |
0 |
59 |
0 |
3 |
8 |
208 |
| The Sustainability of European Health Care Systems: Beyond Income and Ageing |
0 |
0 |
0 |
3 |
2 |
3 |
11 |
57 |
| The Value of Failures in Pharmaceutical R&D |
0 |
0 |
0 |
33 |
0 |
0 |
7 |
158 |
| The evolution of networks of innovators within and across borders: Evidence from patent data |
0 |
0 |
0 |
149 |
1 |
2 |
19 |
253 |
| The potential costs of Longevity Risk on Public Pensions. Evidence from Italian data |
0 |
0 |
0 |
40 |
2 |
3 |
18 |
83 |
| The productivity crisis in pharmaceutical R&D |
0 |
0 |
4 |
184 |
1 |
4 |
32 |
551 |
| Transition drivers and crisis signaling in stock markets |
0 |
0 |
0 |
41 |
0 |
0 |
9 |
45 |
| Who is this, who enters there? - Migration in Italy and its effect on fiscal sustainability and pensions |
0 |
0 |
2 |
113 |
1 |
1 |
15 |
311 |
| Total Working Papers |
2 |
4 |
32 |
5,615 |
44 |
134 |
1,219 |
22,158 |
| Journal Article |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| A Breath of Fresh Air? Firm Type, Scale, Scope, and Selection Effects in Drug Development |
0 |
0 |
1 |
42 |
2 |
3 |
18 |
188 |
| A Comparison of Game-Theoretic Models for Parallel Trade |
0 |
0 |
0 |
5 |
0 |
0 |
8 |
37 |
| A Comparison of U.S. and European University-Industry Relations in the Life Sciences |
0 |
0 |
1 |
16 |
4 |
4 |
17 |
137 |
| A behavioral approach to instability pathways in financial markets |
0 |
0 |
0 |
0 |
0 |
0 |
8 |
17 |
| A generalized preferential attachment model for business firms growth rates |
0 |
0 |
0 |
6 |
0 |
0 |
8 |
28 |
| A generalized preferential attachment model for business firms growth rates |
0 |
0 |
1 |
7 |
0 |
0 |
10 |
44 |
| Assessing financial distress dependencies in OTC markets: a new approach using trade repositories data |
0 |
0 |
1 |
13 |
0 |
0 |
10 |
89 |
| Banks’ business strategies on the edge of distress |
0 |
0 |
0 |
3 |
0 |
0 |
12 |
39 |
| Better to stay apart: asset commonality, bipartite network centrality, and investment strategies |
0 |
0 |
0 |
7 |
0 |
2 |
7 |
34 |
| Climate change and financial stability: Natural disaster impacts on global stock markets |
0 |
0 |
5 |
45 |
5 |
6 |
48 |
157 |
| Commodity prices co-movements and financial stability: A multidimensional visibility nexus with climate conditions |
0 |
0 |
0 |
34 |
1 |
2 |
13 |
109 |
| Dynamic competition in pharmaceuticals |
0 |
0 |
0 |
11 |
0 |
0 |
5 |
45 |
| Economic and social consequences of human mobility restrictions under COVID-19 |
0 |
0 |
3 |
34 |
1 |
2 |
18 |
180 |
| Economic evaluation of HIV treatments: The I.CO.N.A. cohort study |
0 |
0 |
0 |
20 |
0 |
1 |
8 |
111 |
| Financial crises: Uncovering self-organized patterns and predicting stock markets instability |
0 |
0 |
1 |
13 |
0 |
0 |
11 |
47 |
| Financial earthquakes: SARS-CoV-2 news shock propagation in stock and sovereign bond markets |
0 |
0 |
1 |
6 |
1 |
1 |
17 |
30 |
| Innovation and Corporate Dynamics: A Theoretical Framework |
0 |
0 |
0 |
10 |
0 |
1 |
13 |
65 |
| Innovation and corporate growth in the evolution of the drug industry |
0 |
0 |
0 |
161 |
0 |
5 |
20 |
587 |
| Intellectual property, technological regimes and market dynamics |
0 |
0 |
0 |
16 |
0 |
1 |
10 |
66 |
| Intragenerational redistribution in a funded pension system |
0 |
1 |
2 |
18 |
0 |
1 |
16 |
97 |
| La distribuzione dei farmaci tra progetti di riforma e incertezze |
0 |
0 |
0 |
22 |
2 |
2 |
8 |
195 |
| Learning from successes and failures in pharmaceutical R&D |
0 |
0 |
0 |
24 |
0 |
1 |
11 |
125 |
| Long-term correlations in short, non-stationary time series: An application to international R&D collaborations |
0 |
0 |
0 |
1 |
0 |
1 |
13 |
25 |
| Methods to account for citation inflation in research evaluation |
0 |
0 |
0 |
5 |
0 |
4 |
42 |
95 |
| On Innovation, Instability, and Growth. A Review and an Interpretative Framework |
0 |
0 |
0 |
8 |
0 |
0 |
10 |
47 |
| On firm growth in networks |
0 |
0 |
0 |
69 |
0 |
1 |
15 |
197 |
| On size and growth of business firms |
0 |
0 |
0 |
10 |
0 |
0 |
9 |
44 |
| On the size distribution of business firms |
0 |
0 |
0 |
83 |
1 |
4 |
11 |
269 |
| Patent disclosure and R&D competition in pharmaceuticals |
0 |
0 |
1 |
71 |
1 |
2 |
13 |
334 |
| Spatial heterogeneity in non-parametric efficiency: An application to Italian hospitals |
0 |
0 |
0 |
2 |
0 |
0 |
3 |
22 |
| Technological Regimes and the Growth of Networks: An Empirical Analysis |
0 |
0 |
0 |
31 |
0 |
1 |
11 |
135 |
| Technological change and network dynamics: Lessons from the pharmaceutical industry |
0 |
0 |
2 |
186 |
1 |
1 |
23 |
535 |
| The Accounting Network: How Financial Institutions React to Systemic Crisis |
0 |
0 |
0 |
0 |
1 |
3 |
11 |
18 |
| The Evolution of Knowledge and the Dynamics of an Industry Network |
0 |
0 |
0 |
78 |
0 |
1 |
16 |
439 |
| The Growth of Business Firms: Facts and Theory |
0 |
0 |
0 |
114 |
0 |
0 |
7 |
667 |
| The changing boundaries of system companies |
0 |
0 |
0 |
3 |
1 |
1 |
11 |
42 |
| The economic impact of structural and Cohesion Funds across sectors: Immediate, medium-to-long term effects and spillovers |
0 |
0 |
1 |
8 |
1 |
10 |
23 |
51 |
| The evolution of networks of innovators within and across borders: Evidence from patent data |
0 |
0 |
1 |
19 |
0 |
1 |
12 |
91 |
| The intensity of competition after patent expiry in pharmaceuticals. A cross-country analysis |
0 |
0 |
0 |
49 |
0 |
0 |
7 |
151 |
| The memory of science: Inflation, myopia, and the knowledge network |
0 |
0 |
0 |
3 |
0 |
0 |
8 |
34 |
| The network origins of Schumpeterian innovation |
0 |
0 |
0 |
2 |
0 |
1 |
23 |
34 |
| The price of pharmaceutical products in Italy. On some recent trends |
0 |
0 |
0 |
12 |
1 |
2 |
6 |
43 |
| The sustainability of European health care systems: beyond income and aging |
0 |
0 |
0 |
24 |
0 |
0 |
15 |
122 |
| Welfare and research and development incentive effects of uniform and differential pricing schemes |
0 |
0 |
0 |
1 |
0 |
0 |
17 |
22 |
| Total Journal Articles |
0 |
1 |
21 |
1,292 |
23 |
65 |
602 |
5,844 |
LogEc is hosted by the
Örebro University School of Business.